公开(公告)号：US07947672B2

公开(公告)日：2011-05-24

申请号：US10534692

申请日：2003-11-17

Applicant: Avigdor Scherz ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

Inventor： Avigdor Scherz ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

IPC: A61K31/555 ,  A01N55/02 ,  C07B47/00 ,  C07D487/22

CPC classification number: A61N5/062 ,  A61F9/0008 ,  A61K31/40 ,  A61K41/0071 ,  A61K41/0076 ,  A61K49/0036 ,  A61N5/0624 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F13/005 ,  C07F15/006 ,  C07F15/0066 ,  C07F15/045

Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

Abstract translation: 本发明提供阴离子水溶性四环和五环类细菌叶绿素衍生物（Bchls），其含有至少一个，优选两个或三个带负电荷的基团和/或酸性基团，其在生理pH下转化为带负电荷的基团，优选具有基团的Bchls CO 3，SO 3 - ，SO 3 - ，PO 3 2-，COOH，COSH，SO 3 H和/或PO 3 H 2，其通过酯或酰胺键与一个或多个位置17 3， 13 3和3 2的四环或五环Bchl分子，用于光动力学治疗和诊断。

公开(公告)号：US20110117029A1

公开(公告)日：2011-05-19

申请号：US12942938

申请日：2010-11-09

Applicant: Avigdor SCHERZ ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

Inventor： Avigdor SCHERZ ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

IPC: A61K31/555 ,  C07D487/22 ,  C07K17/02 ,  A61K49/00 ,  A01N55/02 ,  A61K39/44 ,  A61P35/00 ,  A61P27/02 ,  A01P1/00

CPC classification number: A61N5/062 ,  A61F9/0008 ,  A61K31/40 ,  A61K41/0071 ,  A61K41/0076 ,  A61K49/0036 ,  A61N5/0624 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F13/005 ,  C07F15/006 ,  C07F15/0066 ,  C07F15/045

Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

Abstract translation: 本发明提供阴离子水溶性四环和五环类细菌叶绿素衍生物（Bchls），其含有至少一个，优选两个或三个带负电荷的基团和/或酸性基团，其在生理pH下转化为带负电荷的基团，优选具有基团的Bchls CO 3，SO 3 - ，SO 3 - ，PO 3 2-，COOH，COSH，SO 3 H和/或PO 3 H 2，其通过酯或酰胺键与一个或多个位置17 3， 13 3和3 2的四环或五环Bchl分子，用于光动力学治疗和诊断。

公开(公告)号：US07944206B2

公开(公告)日：2011-05-17

申请号：US12158364

申请日：2006-12-14

Applicant: Lucio Frydman ,  Boaz Shapira ,  Assaf Tal

Inventor： Lucio Frydman ,  Boaz Shapira ,  Assaf Tal

IPC: G01V3/00

CPC classification number: G01R33/56563 ,  G01R33/4822 ,  G01R33/485 ,  G01R33/5615 ,  G01R33/5616 ,  G01R33/5617

Abstract: A method and apparatus for treating a sample for acquiring high-definition magnetic resonance images (MRI images) or high resolution nuclear magnetic resonance (NMR) spectra even in the presence of magnetic field distortions within one or multiple scans. The spatial nature and temporal dependence of the field inhomogeneities are determined a priori using any of several literature procedures. A static or oscillating magnetic field gradient is applied on the sample so as to endow spins at different positions within the sample with different resonance frequencies. A phase- and amplitude-modulated radiofrequency (RF) pulse is applied in unison with the magnetic field gradient so as to endow spins at different positions within the sample with a homogeneous excitation/inversion profile. The nature of the spatially-selective RF irradiation is tailored in such a way that, when added on top of the effects of the inhomogeneities, the spins' evolution phases and their signal amplitudes at the time of the acquisition become independent of the inhomogeneities. The spin signals thus created are captured and decoded, so as to obtain the spins' response as if the inhomogeneity was not present. The collected data is processed to a suitable rearrangement and Fourier analysis procedure to retrieve a final undistorted image or spectrum. The magnetic field gradient can be oscillated to impose this kind of inhomogeneity corrections on multiple spatial dimensions sequentially, or simultaneously.

Abstract translation: 即使在一次或多次扫描期间存在磁场失真的情况下，也可以用于处理样品以获取高分辨率磁共振图像（MRI图像）或高分辨率核磁共振（NMR）光谱的方法和装置。 使用几种文献程序中的任何一种先验地确定场不均匀性的空间性质和时间依赖性。 对样品施加静态或振荡磁场梯度，以使样品中具有不同共振频率的不同位置旋转。 将相位和幅度调制的射频（RF）脉冲与磁场梯度一致地施加，以便以均匀的激发/反演曲线赋予样品内不同位置的旋转。 空间选择性射频辐射的性质是这样定义的：当在不均匀性的影响之上加入时，获取时的自旋演化阶段和它们的信号幅度变得与不均匀性无关。 如此创建的自旋信号被捕捉和解码，以便获得自旋的响应，就好像不存在不均匀性一样。 将收集的数据处理成合适的重排和傅立叶分析程序以检索最终的未失真图像或光谱。 可以振荡磁场梯度以依次或同时地对多个空间维度施加这种不均匀性校正。

公开(公告)号：US20110093986A1

公开(公告)日：2011-04-21

申请号：US12999814

申请日：2009-06-28

Applicant: Asaph Aharoni ,  Avital Adato ,  Tali Mandel

Inventor： Asaph Aharoni ,  Avital Adato ,  Tali Mandel

IPC: A01H5/00 ,  C07H21/04 ,  C07H21/00 ,  C12Q1/68

CPC classification number: C12N15/825 ,  C07K14/415 ,  C12Q1/6895 ,  C12Q2600/156

Abstract: The present invention discloses that down regulation of the SlMYB12 transcription factor results in the colorless peel y phenotype in tomato fruit. The present invention provides polynucleotides encoding the tomato SlMYB12 transcription factor and genetic markers derived therefrom, useful in the breeding of tomato plants having the colorless peel phenotype and in the production of transgenic plants having altered flavonoid content.

Abstract translation: 本发明公开了SlMYB12转录因子的下调，导致番茄果实无色果皮表型。 本发明提供了编码番茄S1MYB12转录因子的多核苷酸和从其衍生的遗传标记，其可用于育种具有无色剥离表型的番茄植物和在具有改变的类黄酮含量的转基因植物的生产中。

公开(公告)号：US20100322928A1

公开(公告)日：2010-12-23

申请号：US12448937

申请日：2008-01-17

Applicant: Edna Mozes

Inventor： Edna Mozes

IPC: A61K39/395 ,  A61K31/573 ,  A61K31/5377 ,  A61K38/16 ,  A61K31/713 ,  A61P37/02 ,  A61P29/00 ,  C12Q1/68 ,  C40B30/04

CPC classification number: G01N33/564 ,  G01N2800/104

Abstract: A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and/or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE.

Abstract translation: 提供了一种治疗受试者系统性红斑狼疮（SLE）的方法。 该方法包括在细胞中改变选自Mpo，Ltf，Lcn，Camp，Ngp，Slfn，Ctsg，Thbs1，S100a8，1190003K14Rik，Prtn3，S100a9，Tfpi中的至少一种基因的至少一种基因的表达和/ ，Fzd6，Nid1,5830484A20Rik，5830484A20 LOC 545340，Tnfsf4，IPstpip2，Pigr，270022B06Rik，L5R-α，A130040M12Rik，Gpr132，Cd8b1，Dhx9，Cyp11a1，Lmo7，Rnf184，Pstpip2，Hdgfrp3，Ass1和Zbtb20，从而治疗SLE。 还提供诊断SLE和监测SLE治疗的方法。

公开(公告)号：US07855063B2

公开(公告)日：2010-12-21

申请号：US10552287

申请日：2004-04-18

Applicant: Anthony Futerman ,  Joel L. Sussman ,  Israel Silman ,  Michal Harel ,  Hay Dvir ,  Lilly Toker

Inventor： Anthony Futerman ,  Joel L. Sussman ,  Israel Silman ,  Michal Harel ,  Hay Dvir ,  Lilly Toker

IPC: C12N9/26 ,  A61K38/47

CPC classification number: A61K38/47 ,  C12N9/2402 ,  C12Y302/01045 ,  C12Y305/01052 ,  G01N33/573 ,  G01N2500/04

Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule. A glucocerebrosidase preparation comprising a population of glucocerebrosidase molecules, wherein substantially each of said glucocerebrosidase molecules: (i) has an amino acid sequence at least 95 percent homologous to an amino acid sequence set forth by SEQ ID NO: 1 or 8; (ii) is glycosylated at, or has an aspartatic acid residue at, glycosylation residue 1 of said amino acid sequence; and (iii) is independently unglycosylated at one or more glycosylation residues selected from the group consisting of glycosylation residues 2, 3 and 4 of said amino acid sequence.

Abstract translation: 一种鉴定能够校正突变型葡糖脑苷脂酶分子受损的酶活性的化合物的方法，所述方法包括：（a）获得第一组结构坐标，所述第一组结构坐标定义了能够产生以下结构的葡萄糖脑苷脂酶分子的3D结构 显示正常的酶活性或其一部分; （b）使用所述第一组结构坐标计算生成第二组结构坐标，所述第二组结构坐标定义所述突变型葡糖脑苷脂酶分子或其部分的预测3D结构; 和（c）使用第二组结构坐标计算地鉴定能够与突变型葡糖脑苷脂酶分子相互作用的化合物，以便校正受损的酶活性，从而鉴定能够校正受损的酶活性的化合物 突变型葡糖脑苷脂酶分子。 包含一群葡萄糖脑苷脂酶分子的葡糖脑苷脂酶制剂，其中基本上每一种所述的葡糖脑苷脂酶分子：（i）具有与SEQ ID NO：1或8所示的氨基酸序列至少95％同源的氨基酸序列; （ii）在所述氨基酸序列的糖基化残基1处糖基化，或具有天冬氨酸残基; 和（iii）在选自所述氨基酸序列的糖基化残基2,3和4的一个或多个糖基化残基处独立地未糖基化。

公开(公告)号：US20100279928A1

公开(公告)日：2010-11-04

申请号：US12811912

申请日：2009-01-07

Applicant: Menachem RUBINSTEIN

Inventor： Menachem RUBINSTEIN

IPC: A61K38/17 ,  C07K14/705 ,  C07K19/00 ,  C12N15/63 ,  C12N5/10

CPC classification number: A61K38/177 ,  A61K48/00 ,  C07K14/705

Abstract: The invention relates to the use of the souluble LDL receptor (sLDLR) in viral hepatitis.

Abstract translation: 本发明涉及在病毒性肝炎中使用灵芝LDL受体（sLDLR）。

公开(公告)号：US20100279302A1

公开(公告)日：2010-11-04

申请号：US12773977

申请日：2010-05-05

Applicant: Eran Segal ,  Michael Kertesz ,  Howard Y. Chang ,  John Rinn ,  Adam Adler ,  Yue Wan

Inventor： Eran Segal ,  Michael Kertesz ,  Howard Y. Chang ,  John Rinn ,  Adam Adler ,  Yue Wan

IPC: C12Q1/68 ,  G01N33/50

CPC classification number: C12Q1/6827 ,  C12Q1/6809 ,  C12Q1/6811 ,  C12Q1/6869 ,  Y10T436/143333 ,  C12Q2565/133 ,  C12Q2537/143 ,  C12Q2535/122 ,  C12Q2525/191 ,  C12Q2521/501 ,  C12Q2521/301 ,  C12Q2521/307

Abstract: Provided are methods of predicting a pairability of nucleotides of a plurality of RNA polynucleotides by (a) simultaneously determining a paired state or an unpaired state of nucleotides of the plurality of RNA polynucleotides; and (b) corresponding the paired state or the unpaired state of the nucleotides to a database of nucleic acid sequences, the database comprises nucleic acid sequences representing the plurality of RNA polynucleotides, thereby determining the pairability of nucleotides of the plurality of RNA polynucleotides. Also provided are methods of determining a secondary structure of a plurality of RNA molecules; methods of determining if a molecule is capable of modulating a secondary structure of at least one RNA polynucleotide of a plurality of RNA polynucleotides; and methods of screening for a marker associated with a pathology.

Abstract translation: 提供了通过（a）同时确定多个RNA多核苷酸的核苷酸的配对状态或不配对状态来预测多个RNA多核苷酸的核苷酸的配对的方法; 和（b）将核苷酸的配对状态或不配对状态对应于核酸序列的数据库，数据库包括表示多个RNA多核苷酸的核酸序列，从而确定多个RNA多核苷酸的核苷酸的配对性。 还提供了确定多个RNA分子的二级结构的方法; 确定分子是否能够调节多个RNA多核苷酸的至少一个RNA多核苷酸的二级结构的方法; 以及筛选与病理学相关的标志物的方法。

公开(公告)号：US20100221270A1

公开(公告)日：2010-09-02

申请号：US12777292

申请日：2010-05-11

Applicant: Yair REISNER ,  Benjamin Dekel ,  Smadar Eventov-Friedman ,  Helena Katchman ,  Elias Shezen ,  Anna Aronovich ,  Dalit Tchorsh

Inventor： Yair REISNER ,  Benjamin Dekel ,  Smadar Eventov-Friedman ,  Helena Katchman ,  Elias Shezen ,  Anna Aronovich ,  Dalit Tchorsh

IPC: A61K39/00 ,  A61K35/407 ,  A61P1/16

CPC classification number: A61L27/3604 ,  A61K35/22 ,  A61K35/407 ,  A61K35/54 ,  A61K39/39541 ,  A61K45/06 ,  A61L27/3641 ,  A61L27/54 ,  A61L2430/28 ,  A61K2300/00

Abstract: A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.

Abstract translation: 公开了在有需要的受试者中治疗肾，肝或酶缺乏障碍的方法。 该方法通过移植到源自人或猪，肾或肝，肾或肝处于选定妊娠阶段的受试组织中来实现。

公开(公告)号：US07741021B2

公开(公告)日：2010-06-22

申请号：US11595319

申请日：2006-11-09

Applicant: Alma L. Burlingame ,  Katalin F. Medzihradszky ,  Zsuzsanna Darula ,  Eran Perlson ,  Michael Fainzilber ,  Robert J. Chalkley ,  Darren Tyson ,  Ralph A. Bradshaw

Inventor： Alma L. Burlingame ,  Katalin F. Medzihradszky ,  Zsuzsanna Darula ,  Eran Perlson ,  Michael Fainzilber ,  Robert J. Chalkley ,  Darren Tyson ,  Ralph A. Bradshaw

IPC: C12Q1/00 ,  C12Q1/48 ,  C12Q1/37

CPC classification number: G01N33/6842 ,  C07K16/44 ,  C07K2317/21 ,  C07K2317/622 ,  G01N33/6803

Abstract: Post-translational O-sulfonation of a serine or threonine residue of proteins is detected, optionally comparatively, wherein the detected O-sulfonation is detected under a first physiological condition, and is compared with a control O-sulfonation detected under a second physiological condition, and a difference between the detected and control O-sulfonations indicates a difference between the first and second physiological conditions.Predetermined changes in physiological conditions are used to infer specific changes in O-sulfonation. Proteins are modified by introducing a predetermined change in O-sulfonation at a serine or threonine residue of the protein, and optionally, detecting a resultant change in O-sulfonation. These methods include introducing or increasing O-sulfonation, eliminating or reducing O-sulfonation; and derivatizing or substituting O-sulfonation.

Abstract translation: 检测蛋白质丝氨酸或苏氨酸残基的翻译后O-磺化，任选比较，其中在第一生理条件下检测到检测到的O-磺化，并与在第二生理条件下检测到的对照O-磺化进行比较， 并且检测到和控制的O-磺化物之间的差异表示第一和第二生理条件之间的差异。 使用生理条件的预定变化来推测O-磺化的具体变化。 通过在蛋白质的丝氨酸或苏氨酸残基处引入O-磺化的预定变化，并任选地检测所得到的O-磺化变化来修饰蛋白质。 这些方法包括引入或增加O-磺化，消除或减少O-磺化; 并衍生化或取代O-磺化。